Cost-utility model of brivaracetam in the adjunctive treatment of patients with epilepsy in Spain

Vista sencilla de ítem
dc.contributor.affiliationFacultad de Administración y Dirección de Empresas
dc.contributor.affiliationDepartamento de Economía y Ciencias Sociales
dc.contributor.affiliationCentro de Investigación de Ingeniería Económica
dc.contributor.authorBarrachina Martínez, Isabel
dc.contributor.authorVivas-Consuelo, David
dc.contributor.authorReyes-Santias, Franciscoes_ES
dc.date.accessioned2021-05-25T03:32:31Z
dc.date.available2021-05-25T03:32:31Z
dc.date.issued2020-11-06es_ES
dc.description.abstract[EN] Objective This study aims to assess the cost utility of Brivaracetam compared with the third-generation anti-epileptic drugs used as standard care. Methods A cost utility analysis of Brivaracetam was carried out with other third-generation comparators. The treatment pathway of a hypothetical cohort over a period of 2 years was simulated using the Markov model. Data for effectiveness and the QALYs of each health status for epilepsy, as well as for the disutilities of adverse events of treatments, were analyzed through a studies review. The cost of the anti-epileptics and the use of medical resources linked to the different health statuses were taken into consideration. A probabilistic sensitivity analysis was performed using a Monte Carlo simulation. Results Brivaracetam was shown to be the dominant alternative, with Incremental Cost Utility Ratio (ICUR) values from -11,318 for Lacosamide to -128,482 for Zonisamide. The probabilistic sensitivity analysis validates these results. The ICUR sensitivity is greater for increases in the price of Brivaracetam than for decreases, and for Eslicarbizapine over the other adjunctives considered in the analysis. Conclusions Treatment with Brivaracetam resulted in cost effective and incremental quality adjusted life years come at an acceptable cost.en_EN
dc.description.accrualMethodSes_ES
dc.description.bibliographicCitationBarrachina Martínez, I.; Vivas-Consuelo, D.; Reyes-Santias, F. (2020). Cost-utility model of brivaracetam in the adjunctive treatment of patients with epilepsy in Spain. Expert review of pharmacoeconomics & outcomes research (Online). 1-10. https://doi.org/10.1080/14737167.2021.1838899es_ES
dc.description.referencesWHO | Epilepsy: aISBN public health imperative. ISBN 978-92-4-151593-1. World Health Organization. 2019. Printed in Thailand.es_ES
dc.description.referencesNgugi, A. K., Kariuki, S. M., Bottomley, C., Kleinschmidt, I., Sander, J. W., & Newton, C. R. (2011). Incidence of epilepsy: A systematic review and meta-analysis. Neurology, 77(10), 1005-1012. doi:10.1212/wnl.0b013e31822cfc90es_ES
dc.description.referencesHenning, O., Landmark, C. J., Henning, D., Nakken, K. O., & Lossius, M. I. (2019). Challenges in epilepsy—The perspective of Norwegian epilepsy patients. Acta Neurologica Scandinavica, 140(1), 40-47. doi:10.1111/ane.13098es_ES
dc.description.referencesBrodie, M. J. (2005). Diagnosing and predicting refractory epilepsy. Acta Neurologica Scandinavica, 112(s181), 36-39. doi:10.1111/j.1600-0404.2005.00507.xes_ES
dc.description.referencesGarcía-Ramos, R., Pastor, A. G., Masjuan, J., Sánchez, C., & Gil, A. (2011). FEEN: Informe sociosantario FEEN sobre la epilepsia en España. Neurología, 26(9), 548-555. doi:10.1016/j.nrl.2011.04.002es_ES
dc.description.referencesKwan, P., & Brodie, M. J. (2000). Early Identification of Refractory Epilepsy. New England Journal of Medicine, 342(5), 314-319. doi:10.1056/nejm200002033420503es_ES
dc.description.referencesBrodie, M. J. (2008). Epilepsy: randomised trials and genetic tribulations. The Lancet Neurology, 7(1), 7-8. doi:10.1016/s1474-4422(07)70301-0es_ES
dc.description.referencesFrench, J. A. (2006). Refractory Epilepsy: One Size Does Not Fit All. Epilepsy Currents, 6(6), 177-180. doi:10.1111/j.1535-7511.2006.00137.xes_ES
dc.description.referencesLaxer, K. D., Trinka, E., Hirsch, L. J., Cendes, F., Langfitt, J., Delanty, N., … Benbadis, S. R. (2014). The consequences of refractory epilepsy and its treatment. Epilepsy & Behavior, 37, 59-70. doi:10.1016/j.yebeh.2014.05.031es_ES
dc.description.referencesGiordano, C., Marchiò, M., Timofeeva, E., & Biagini, G. (2014). Neuroactive Peptides as Putative Mediators of Antiepileptic Ketogenic Diets. Frontiers in Neurology, 5. doi:10.3389/fneur.2014.00063es_ES
dc.description.referencesEuropean Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Briviact brivaracetam. Assessment Report EMA/CHMP/822086/2015 Nov.es_ES
dc.description.referencesMarkham, A. (2016). Brivaracetam: First Global Approval. Drugs, 76(4), 517-522. doi:10.1007/s40265-016-0555-6es_ES
dc.description.referencesWillems, L. M., Bauer, S., Rosenow, F., & Strzelczyk, A. (2019). Recent advances in the pharmacotherapy of epilepsy: brivaracetam and perampanel as broad-spectrum antiseizure drugs for the treatment of epilepsies and status epilepticus. Expert Opinion on Pharmacotherapy, 20(14), 1755-1765. doi:10.1080/14656566.2019.1637420es_ES
dc.description.referencesCraig, D., Rice, S., Paton, F., Fox, D., & Woolacott, N. (2013). Retigabine for the Adjunctive Treatment of Adults with Partial-Onset Seizures in Epilepsy with and without Secondary Generalization. PharmacoEconomics, 31(2), 101-110. doi:10.1007/s40273-012-0018-1es_ES
dc.description.referencesCharokopou, M., Harvey, R., Srivastava, K., Brandt, C., & Borghs, S. (2019). Relative performance of brivaracetam as adjunctive treatment of focal seizures in adults: a network meta-analysis. Current Medical Research and Opinion, 35(8), 1345-1354. doi:10.1080/03007995.2019.1584501es_ES
dc.description.referencesChhatwal J. Changing cycle lengths in state-transition models: doing it the right way; [cited 2018 Jan 23]. Available from: https://www.ispor.org/News/Connections_methodology_state-transition-models.PDFes_ES
dc.description.referencesMulhern, B., Rowen, D., Snape, D., Jacoby, A., Marson, T., Hughes, D., … Brazier, J. (2014). Valuations of epilepsy-specific health states: a comparison of patients with epilepsy and the general population. Epilepsy & Behavior, 36, 12-17. doi:10.1016/j.yebeh.2014.04.011es_ES
dc.description.referencesKristian, B., Wachtmeister, K., Stefan, F., & Forsgren, L. (2013). Retigabine as add-on treatment of refractory epilepsy - a cost-utility study in a Swedish setting. Acta Neurologica Scandinavica, 127(6), 419-426. doi:10.1111/ane.12077es_ES
dc.description.referencesVera-Llonch, M., Brandenburg, N. A., & Oster, G. (2008). Cost-effectiveness of Add-on Therapy with Pregabalin in Patients with Refractory Partial Epilepsy. Epilepsia, 49(3), 431-437. doi:10.1111/j.1528-1167.2007.01279.xes_ES
dc.description.referencesSimoens, S. (2010). Pharmacoeconomics of anti-epileptic drugs as adjunctive therapy for refractory epilepsy. Expert Review of Pharmacoeconomics & Outcomes Research, 10(3), 309-315. doi:10.1586/erp.10.18es_ES
dc.description.referencesWijnen, B. F. M., van Mastrigt, G. A. P. G., Evers, S. M. A. A., Gershuni, O., Lambrechts, D. A. J. E., Majoie, M. H. J. M., … de Kinderen, R. J. A. (2017). A systematic review of economic evaluations of treatments for patients with epilepsy. Epilepsia, 58(5), 706-726. doi:10.1111/epi.13655es_ES
dc.description.referencesBoeck, J. D., Verpoorten, K., Luyten, K., & Coninx, K. (2007). A Comparison between Decision Trees and Markov Models to Support Proactive Interfaces. 18th International Conference on Database and Expert Systems Applications (DEXA 2007). doi:10.1109/dexa.2007.94es_ES
dc.description.referencesZhang, Y., Wu, H., Denton, B. T., Wilson, J. R., & Lobo, J. M. (2017). Probabilistic sensitivity analysis on Markov models with uncertain transition probabilities: an application in evaluating treatment decisions for type 2 diabetes. Health Care Management Science, 22(1), 34-52. doi:10.1007/s10729-017-9420-8es_ES
dc.description.referencesSwallow, E., Fang, A., Signorovitch, J., Plumb, J., & Borghs, S. (2017). Can Matching-Adjusted Indirect Comparison Methods Mitigate Placebo Response Differences Among Patient Populations in Adjunctive Trials of Brivaracetam and Levetiracetam? CNS Drugs, 31(10), 899-910. doi:10.1007/s40263-017-0462-8es_ES
dc.description.referencesMalyshkina NV, Mannering FL. Markov switching multinomial logit model: an application to accident injury severities; 2008 [cited 2019 Sep 25]. Available from: http://arxiv.org/abs/0811.3644es_ES
dc.description.referencesHawkins, N., Epstein, D., Drummond, M., Wilby, J., Kainth, A., Chadwick, D., & Sculpher, M. (2005). Assessing the Cost-Effectiveness of New Pharmaceuticals in Epilepsy in Adults: The Results of a Probabilistic Decision Model. Medical Decision Making, 25(5), 493-510. doi:10.1177/0272989x05280559es_ES
dc.description.referencesAgencia Española del Medicamento. Utilización de medicamentos antiepilépticos en España durante el periodo 2008–2016 [Internet]; 2017 [cited 2019 Sep 25]. Available from: https://www.aemps.gob.es/medicamentosUsoHumano/observatorio/docs/antiepilepticos-periodo-2008-2016.pdfes_ES
dc.description.referencesMegiddo, I., Colson, A., Chisholm, D., Dua, T., Nandi, A., & Laxminarayan, R. (2016). Health and economic benefits of public financing of epilepsy treatment in India: An agent‐based simulation model. Epilepsia, 57(3), 464-474. doi:10.1111/epi.13294es_ES
dc.description.referencesDe Andrés-Nogales, F., Oyagüez, I., Álvarez-Sala, L. A., García-Bragado, F., Navarro, A., González, P., … Soto, J. (2017). Análisis coste-efectividad y coste-utilidad de apixaban frente a dabigatrán y rivaroxaban en el tratamiento y prevención secundaria del tromboembolismo venoso. PharmacoEconomics Spanish Research Articles, 14(1), 7-18. doi:10.1007/s40277-016-0064-8es_ES
dc.description.referencesFricke-Galindo, I., Jung-Cook, H., LLerena, A., & López-López, M. (2018). Farmacogenética de reacciones adversas a fármacos antiepilépticos. Neurología, 33(3), 165-176. doi:10.1016/j.nrl.2015.03.005es_ES
dc.description.referencesSteinhoff, B. J., Bacher, M., Bucurenciu, I., Hillenbrand, B., Intravooth, T., Kornmeier, R., … Staack, A. M. (2017). Real-life experience with brivaracetam in 101 patients with difficult-to-treat epilepsy—A monocenter survey. Seizure, 48, 11-14. doi:10.1016/j.seizure.2017.03.010es_ES
dc.description.referencesDe Kinderen, R. J. A., Wijnen, B. F. M., van Breukelen, G., Postulart, D., Majoie, M. H. J. M., Aldenkamp, A. P., & Evers, S. M. A. A. (2016). From clinically relevant outcome measures to quality of life in epilepsy: A time trade-off study. Epilepsy Research, 125, 24-31. doi:10.1016/j.eplepsyres.2016.05.005es_ES
dc.description.referencesCortés, J.-C., Navarro-Quiles, A., Romero, J.-V., & Roselló, M.-D. (2017). Randomizing the parameters of a Markov chain to model the stroke disease: A technical generalization of established computational methodologies towards improving real applications. Journal of Computational and Applied Mathematics, 324, 225-240. doi:10.1016/j.cam.2017.04.040es_ES
dc.description.upvformatpfin10es_ES
dc.description.upvformatpinicio1es_ES
dc.identifier.doi10.1080/14737167.2021.1838899es_ES
dc.identifier.eissn1744-8379es_ES
dc.identifier.pmid33074031es_ES
dc.identifier.urihttps://riunet.upv.es/handle/10251/166746
dc.languageIngléses_ES
dc.publisherTaylor & Francises_ES
dc.relation.ispartofExpert review of pharmacoeconomics & outcomes research (Online)es_ES
dc.relation.pasarelaS\421035es_ES
dc.relation.publisherversionhttps://doi.org/10.1080/14737167.2021.1838899es_ES
dc.relation.references10.1212/WNL.0b013e31822cfc90es_ES
dc.relation.references10.1111/ane.13098es_ES
dc.relation.references10.1111/j.1600-0404.2005.00507.xes_ES
dc.relation.references10.1016/j.nrl.2011.04.002es_ES
dc.relation.references10.1056/NEJM200002033420503es_ES
dc.relation.references10.1016/S1474-4422(07)70301-0es_ES
dc.relation.references10.1111/j.1535-7511.2006.00137.xes_ES
dc.relation.references10.1016/j.yebeh.2014.05.031es_ES
dc.relation.references10.3389/fneur.2014.00063es_ES
dc.relation.references10.1007/s40265-016-0555-6es_ES
dc.relation.references10.1080/14656566.2019.1637420es_ES
dc.relation.references10.1007/s40273-012-0018-1es_ES
dc.relation.references10.1080/03007995.2019.1584501es_ES
dc.relation.references10.1016/j.yebeh.2014.04.011es_ES
dc.relation.references10.1111/ane.12077es_ES
dc.relation.references10.1111/j.1528-1167.2007.01279.xes_ES
dc.relation.references10.1586/erp.10.18es_ES
dc.relation.references10.1111/epi.13655es_ES
dc.relation.references10.1109/DEXA.2007.94es_ES
dc.relation.references10.1007/s10729-017-9420-8es_ES
dc.relation.references10.1007/s40263-017-0462-8es_ES
dc.relation.references10.1177/0272989X05280559es_ES
dc.relation.references10.1111/epi.13294es_ES
dc.relation.references10.1007/s40277-016-0064-8es_ES
dc.relation.references10.1016/j.nrl.2015.03.005es_ES
dc.relation.references10.1016/j.seizure.2017.03.010es_ES
dc.relation.references10.1016/j.eplepsyres.2016.05.005es_ES
dc.relation.references10.1016/j.cam.2017.04.040es_ES
dc.rightsReserva de todos los derechoses_ES
dc.rights.accessRightsAbiertoes_ES
dc.subjectAdjunctive therapyes_ES
dc.subjectAnti-epileptic drugses_ES
dc.subjectCost utilityes_ES
dc.subjectMarkov modeles_ES
dc.subjectMonte Carlo simulationes_ES
dc.subject.classificationECONOMIA APLICADAes_ES
dc.subject.classificationECONOMIA FINANCIERA Y CONTABILIDADes_ES
dc.subject.ods03.- Garantizar una vida saludable y promover el bienestar para todos y todas en todas las edadeses_ES
dc.titleCost-utility model of brivaracetam in the adjunctive treatment of patients with epilepsy in Spaines_ES
dc.typeArtículoes_ES
dc.type.versioninfo:eu-repo/semantics/publishedVersiones_ES
dspace.entity.typePublication
person.identifier10887
person.identifier3295
person.identifier.orcid0000-0003-3710-1190
person.identifier.orcid0000-0003-2945-7525
relation.isAuthorOfPublication52496dc2-8ade-4e26-884d-b638b8bf7ee3
relation.isAuthorOfPublication9eb26f59-52eb-4a08-ba5e-117b5bffaf34
relation.isAuthorOfPublication.latestForDiscovery52496dc2-8ade-4e26-884d-b638b8bf7ee3
relation.isOrgUnitOfPublication67c03db1-c7ed-41d2-8506-f61e5b5de340
relation.isOrgUnitOfPublication1562846a-1e62-49bb-a253-92b3901edd08
relation.isOrgUnitOfPublication9d1201bc-605c-42e9-bda0-396da3916581
relation.isOrgUnitOfPublication.latestForDiscovery67c03db1-c7ed-41d2-8506-f61e5b5de340
upv.uuid45e701ef-e004-49c4-a886-e88acb5d4b81es_ES

Archivos

Bloque original

Mostrando 1 - 2 de 2
Miniatura
Nombre:
Barrachna;Vvas-Consuelo;Reyes-Santas - Cost-utlty model of brvaracetamn the adjunctve treatment o....pdf
Tamaño:
1.73 MB
Formato:
Adobe Portable Document Format
Descripción:
Versión del Autor.
[object Object] Descargar
Miniatura
Nombre:
Cost utility model of brivaracetam in the adjunctive treatment of patients with epilepsy in Spain.pdf
Tamaño:
2.56 MB
Formato:
Adobe Portable Document Format
Descripción:
Versión editorial
Descargar

Colecciones

Artículos, conferencias, monografías